AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma
Anila Hashmi, Alexander Papachristos, Stan Sidhu, Gyorgy Hutvagner · 2024
Read AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma by Anila Hashmi, Alexander Papachristos, Stan Sidhu, Gyorgy Hutvagner (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11623120.txt.
Description
Anila Hashmi, Alexander Papachristos, Stan Sidhu, and Gyorgy Hutvagner test a protein as a marker for a rare adrenal cancer in this 2024 paper. Adrenocortical carcinoma is uncommon but fierce: hard to diagnose, quick to return, and often deadly. Better markers would help on all three fronts.
The team examined the machinery that processes microRNAs, tiny gene regulators, in tumor data from large public atlases. They also measured the proteins directly in banked tissue. One part stood out: AGO2, the enzyme that carries out microRNA silencing, ran far higher in cancers than in healthy adrenal tissue or benign lumps. Patients with higher AGO2 also fared worse in survival analysis. The authors propose AGO2 as a candidate marker to flag the cancer and to warn of a harder course.
Catalog record
| CREATOR | Anila Hashmi, Alexander Papachristos, Stan Sidhu, Gyorgy Hutvagner |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |